These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25179681)

  • 1. Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.
    Xue T; Ding S; Guo B; Zhou Y; Sun P; Wang H; Chu W; Gong G; Wang Y; Chen X; Yang Y
    J Med Chem; 2014 Sep; 57(18):7770-91. PubMed ID: 25179681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors.
    Yang J; Su G; Ren Y; Chen Y
    Eur J Med Chem; 2015 Aug; 101():41-51. PubMed ID: 26114810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling studies of [6,6,5] Tricyclic Fused Oxazolidinones as FXa inhibitors using 3D-QSAR, Topomer CoMFA, molecular docking and molecular dynamics simulations.
    Xu C; Ren Y
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4522-8. PubMed ID: 26343829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
    Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
    Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.
    Orwat MJ; Qiao JX; He K; Rendina AR; Luettgen JM; Rossi KA; Xin B; Knabb RM; Wexler RR; Lam PY; Pinto DJ
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3341-5. PubMed ID: 24951330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
    Xing J; Yang L; Yang Y; Zhao L; Wei Q; Zhang J; Zhou J; Zhang H
    Eur J Med Chem; 2017 Jan; 125():411-422. PubMed ID: 27689724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors.
    Zhao Y; Jiang M; Zhou S; Wu S; Zhang X; Ma L; Zhang K; Gong P
    Eur J Med Chem; 2015; 96():369-80. PubMed ID: 25911624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors.
    Imaeda Y; Kuroita T; Sakamoto H; Kawamoto T; Tobisu M; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
    J Med Chem; 2008 Jun; 51(12):3422-36. PubMed ID: 18507371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
    Roehrig S; Straub A; Pohlmann J; Lampe T; Pernerstorfer J; Schlemmer KH; Reinemer P; Perzborn E
    J Med Chem; 2005 Sep; 48(19):5900-8. PubMed ID: 16161994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.
    Xing J; Yang L; Li H; Li Q; Zhao L; Wang X; Zhang Y; Zhou M; Zhou J; Zhang H
    Eur J Med Chem; 2015 May; 95():388-99. PubMed ID: 25839438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
    Wang Y; Sun X; Yang D; Guo Z; Fan X; Nie M; Zhang F; Liu Y; Li Y; Wang Y; Gong P; Liu Y
    Bioorg Med Chem; 2016 Nov; 24(21):5646-5661. PubMed ID: 27663548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative Three-Step Microwave-Promoted Synthesis of
    Santana-Romo F; Lagos CF; Duarte Y; Castillo F; Moglie Y; Maestro MA; Charbe N; Zacconi FC
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
    Sun X; Hong Z; Liu M; Guo S; Yang D; Wang Y; Lan T; Gao L; Qi H; Gong P; Liu Y
    Bioorg Med Chem; 2017 May; 25(10):2800-2810. PubMed ID: 28389110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review.
    Khadse AN; Sharma MK; Murumkar PR; Rajput SJ; Yadav MR
    Mini Rev Med Chem; 2018; 18(16):1332-1353. PubMed ID: 29692238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
    Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semisynthesis of ent-norstrobane diterpenoids as potential inhibitor for factor Xa.
    Wang J; Ma H; Fu H
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3813-3815. PubMed ID: 30340898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.
    Hirayama F; Koshio H; Ishihara T; Hachiya S; Sugasawa K; Koga Y; Seki N; Shiraki R; Shigenaga T; Iwatsuki Y; Moritani Y; Mori K; Kadokura T; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    J Med Chem; 2011 Dec; 54(23):8051-65. PubMed ID: 21995444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Koch S; Rossi KA; Alexander RS; Smallwood A; Wong PC; Rendina AR; Luettgen JM; Knabb RM; He K; Xin B; Wexler RR; Lam PY
    J Med Chem; 2007 Nov; 50(22):5339-56. PubMed ID: 17914785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potent orally active factor Xa inhibitors based on conjugation strategy and application of predictable fragment recommender system.
    Ishihara T; Koga Y; Iwatsuki Y; Hirayama F
    Bioorg Med Chem; 2015 Jan; 23(2):277-89. PubMed ID: 25523211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.